Collegeville, PA, United States of America

Dai-Shi Su

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 8.5

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Dai-Shi Su

Introduction

Dai-Shi Su is a notable inventor based in Collegeville, PA, who has made significant contributions to the field of pharmaceutical sciences. With a total of three patents to his name, his work focuses on developing novel compounds that address various metabolic and psychiatric disorders.

Latest Patents

One of Dai-Shi Su's latest patents is related to Ghrelin O-acyltransferase inhibitors. This invention involves novel compounds that inhibit ghrelin O-acyltransferase (GOAT) and includes pharmaceutical compositions for treating metabolic disorders such as Prader-Willi syndrome, metabolic syndrome, and type II diabetes mellitus. Another significant patent is for Enhancer of Zeste Homolog 2 inhibitors, which are also novel compounds aimed at inhibiting EZH2 and include pharmaceutical compositions for therapeutic use.

Career Highlights

Dai-Shi Su has worked with prominent companies in the pharmaceutical industry, including GlaxoSmithKline Intellectual Property Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Dai-Shi Su has collaborated with notable colleagues such as Charles William Blackledge, Jr. and Joelle Lorraine Burgess, enhancing the scope and impact of his research and inventions.

Conclusion

Dai-Shi Su's innovative work in developing inhibitors for metabolic and psychiatric disorders showcases his commitment to advancing pharmaceutical science. His contributions are significant in addressing complex health issues and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…